Company news
Tempest Therapeutics, Inc. (NASDAQ:TPST) news
Tempest Therapeutics, Inc. news releases on 6ix. Latest, May 9, 2024: Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
Press releases — page 2
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
April 8, 2024
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
April 3, 2024
Tempest Reports Year End 2023 Financial Results and Provides Business Update
March 18, 2024
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
March 4, 2024
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
November 7, 2023
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
October 10, 2023
Tempest Adopts Limited Duration Stockholder Rights Plan
October 10, 2023
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
September 18, 2023
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
July 18, 2023
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
May 24, 2023
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
May 9, 2023
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
April 27, 2023
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
April 26, 2023
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
April 25, 2023
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
April 16, 2023
Tempest Reports Year End 2022 Financial Results and Provides Business Update
March 21, 2023
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer
November 9, 2022
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting
November 1, 2022
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
August 14, 2022
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
May 12, 2022
Tempest Announces Private Placement Financing of $15 Million
April 26, 2022
Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting
April 26, 2022
Tempest Reports Year End 2021 Financial Results and Provides Business Update
March 28, 2022
Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
November 17, 2021
Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer
November 11, 2021
Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights
November 9, 2021
Tempest to Present at Two Upcoming Investor Conferences in November
November 8, 2021
Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
September 30, 2021
Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
September 19, 2021
Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights
August 11, 2021
Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors
August 8, 2021
Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
June 30, 2021
Tempest and Millendo Announce Stockholder Approval of Merger
June 21, 2021
Tempest and Millendo Announce Proposed Merger Agreement
March 28, 2021